Agios Pharmaceuticals (NASDAQ:AGIO) will release its earnings data before the market opens on Wednesday, February 14th. Analysts expect Agios Pharmaceuticals to post earnings of ($1.65) per share for the quarter.
Shares of Agios Pharmaceuticals (NASDAQ AGIO) opened at $76.82 on Wednesday. The company has a market cap of $3,750.00, a P/E ratio of -12.25 and a beta of 2.12. Agios Pharmaceuticals has a 1 year low of $43.32 and a 1 year high of $82.96.
Several research firms have recently commented on AGIO. ValuEngine upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Royal Bank of Canada upped their price objective on shares of Agios Pharmaceuticals to $91.00 and gave the company an “outperform” rating in a research note on Thursday, January 18th. They noted that the move was a valuation call. BidaskClub raised shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, January 16th. Zacks Investment Research raised shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating and set a $84.00 price objective on the stock in a research note on Tuesday, January 16th. Finally, Oppenheimer set a $83.00 price objective on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, January 1st. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Agios Pharmaceuticals has an average rating of “Buy” and a consensus target price of $77.64.
COPYRIGHT VIOLATION NOTICE: “Agios Pharmaceuticals (AGIO) Scheduled to Post Earnings on Wednesday” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/07/agios-pharmaceuticals-agio-scheduled-to-post-earnings-on-wednesday.html.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.